Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 516-517

  Pieri, Lisa ^a   Guglielmelli, Paola ^a   Bogani, Costanza ^a   Bosi, Alberto ^a   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; CD45 ANTIGEN; COLLAGEN FIBER; CYTOKINE; JANUS KINASE 2; MUTANT PROTEIN; RETICULIN; THROMBOPOIETIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR GATA 1;

ALLELE; BONE BIOPSY; BONE MARROW CELL; CELL CULTURE; CELL INTERACTION; CELL PROLIFERATION; DENSITY GRADIENT; DISEASE COURSE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MEGAKARYOCYTE; MESENCHYMAL STEM CELL; MOLECULAR CLONING; MYELOID METAPLASIA; POLYCYTHEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; CELLS, CULTURED; HUMANS; JANUS KINASE 2; MESENCHYMAL STEM CELLS; MUTATION; MYELOFIBROSIS;

EID: 39749128709     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.001     Document Type: Letter

References (11)

1. Tefferi A. Primary myelofibrosis and its paraneoplastic stromal effects. Haematologica 92 (2007) 577-579
2. Castro-Malaspina H., Gay R.E., Jhanwar S.C., Hamilton J.A., Chiarieri D.R., Meyers P.A., et al. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood 59 (1982) 1046-1054
3. Brouty-Boye D., Doucet C., Clay D., Le Bousse-Kerdiles M.C., Lampidis T.J., and Azzarone B. Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues. Int J Cancer 76 (1998) 767-773
4. Deeg H.J., Gooley T.A., Flowers M.E., Sale G.E., Slattery J.T., Anasetti C., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
5. Vannucchi A.M., Migliaccio A.R., Paoletti F., Chagraoui H., and Wendling F. Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease. Semin Oncol 32 (2005) 365-372
6. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 7 (2006) e270
7. V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
8. Xu M., Bruno E., Chao J., Ni H., Lindgren V., Nunez R., et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 105 (2005) 1699-1705
9. Rosti V., Massa M., Vannucchi A.M., Bergamaschi G., Campanelli R., Pecci A., et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 38 (2007) 280-286
10. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 13 (2006) 419-425
11. Vannucchi A.M., Pancrazzi A., Bogani C., Antonioli E., and Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 20 (2006) 1055-1060